

health 17.1 percent; allied health 18.2 percent; and clinical psychology 18 percent.

Nonstatutory Special Consideration for Baccalaureate Nursing Programs

Among schools of nursing, additional special consideration will be given to baccalaureate programs. One of the distinguishing features of baccalaureate education is the substantial focus on preparation for community health practice. Training nurses for community health practice is an integral component of the Department's access strategy.

It is not required that new applicants request consideration for a funding factor. Applications from new schools which do not request consideration for funding factors will be reviewed and given full consideration for funding.

Procedures for Calculating Awards

Awards to eligible schools will be calculated by comparing the enrollment of disadvantaged students in each eligible school with the total enrollment of the disadvantaged students in all eligible schools.

A school with an enrollment of underrepresented minority students which is above the national average (for each discipline) will be given double credit (i.e., its enrollment of disadvantaged students would be doubled for awarding purposes). A baccalaureate nursing school will be given double credit. A baccalaureate nursing school with an underrepresented minority enrollment above the national average will be given quadruple credit (i.e., its enrollment of disadvantaged students will be multiplied by four for awarding purposes).

Other Consideration

Other funding factors may be applied in determining the funding of eligible schools.

A funding preference is defined as the funding of a specific category or group of eligible schools ahead of other categories or groups of eligible schools.

A funding priority is defined as the favorable adjustment of aggregate review scores of individual approved applications when applications meet specified criteria.

It is not required that new applicants request consideration for a funding factor. Applications from new schools which do not request consideration for funding factors will be reviewed and given full consideration for funding.

Funding Preference and Priority

For fiscal year 1997, among allied health schools or programs, preference

will be given to the following baccalaureate and graduate programs: dental hygiene, medical laboratory technology, occupational therapy, physical therapy and radiologic technology. In addition, priority among allied health applicants will be given to dental hygiene. A priority for dental hygiene will be implemented by taking the total funds allocated to the allied health disciplines in the initial allocation and recalculating this part of the allocation. Dental hygiene schools will receive double credit for their disadvantaged enrollments in the reallocation of the allied health funds.

National Health Objectives for the Year 2000

The Public Health Service is committed to achieving the health promotion and disease prevention objectives of Healthy People 2000, a PHS-led national activity for setting priority areas. The Scholarships for Disadvantaged Students program is related to the priority area of Academic and Community Partnership Programs. Potential applicants may obtain a copy of *Healthy People 2000* (Full Report; Stock No. 017-001-00474-0) or *Healthy People 2000* (Summary Report; Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, D.C. 20402-9325 (Telephone (202) 783-3238).

Smoke-Free Workplace

The Public Health Service strongly encourages all award recipients to provide a smoke-free workplace and promote the non-use of all tobacco products, and Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities that receive Federal funds in which education, library, day care, health care, and early childhood development services are provided to children.

Application Requests

Applications are not required from schools of medicine, osteopathic medicine, dentistry, pharmacy, optometry, podiatric medicine, veterinary medicine, nursing, public health, clinical psychology and allied health which received SDS awards in FY 1996. Upon request, materials will be mailed to schools in the disciplines identified above which did not participate in the SDS program in FY 1996.

Requests for materials and questions regarding business management and program policy should be directed to: Office for Campus Based Programs, Division of Student Assistance, Bureau

of Health Professions, Health Resources and Services Administration, Parklawn Building, Room 8-34, 5600 Fishers Lane, Rockville, Maryland 20857. Telephone: (301) 443-4776; FAX: (301) 443-0846.

The deadline date for submitting materials from new schools is April 21, 1997. Applications shall be considered as meeting the deadline if they are either:

- (1) *Received on or before* the established deadline date, or
- (2) *Sent on or before* the established deadline and received in time for orderly processing. (Applicants should request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.)

Late applications not accepted for processing will be returned to the applicant.

The materials for this program (SF 269) have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act. The OMB clearance number is 0348-0039. In addition, applicants are required to provide certification that there is at least one minority faculty member on staff at the applicant institution.

The Catalog of Federal Domestic Assistance Number for the Scholarships for Disadvantaged Students program is 93.925. This program is not subject to the provisions of Executive Order 12372, Intergovernmental Review of Federal Programs (as implemented through 45 CFR part 100).

This program is not subject to the Public Health System Reporting Requirements.

Dated: March 13, 1997.

Ciro V. Sumaya,

Administrator.

[FR Doc. 97-7140 Filed 3-20-97; 8:45 am]

BILLING CODE 4160-15-P

Public Health Service

Notice Regarding Section 602 of the Veterans Health Care Act of 1992—Withdrawal of Rebate Mechanism

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: Section 602 of Public Law 102-585, the "Veterans Health Care Act of 1992," enacted section 340B of the Public Health Service Act, "Limitation on Prices of Drugs Purchased by Covered Entities." Section 340B

provides that a manufacturer who sells covered outpatient drugs to eligible (covered) entities must sign a pharmaceutical pricing agreement with the Secretary of HHS in which the manufacturer agrees to charge a price for covered outpatient drugs that will not exceed that amount determined under a statutory formula.

The purpose of this notice is to withdraw the **Federal Register** notice entitled, "Notice Regarding Section 602 of the Veterans Health Care Act of 1992—Rebate Mechanism," published on March 14, 1997. This notice requested comments on the proposal of a rebate process for State AIDS Drug Assistance Programs receiving funds under Title XXVI of the PHS Act.

FOR FURTHER INFORMATION CONTACT: Annette Byrne, R. Ph., Director, Office of Drug Pricing, Bureau of Primary Health Care, Health Resources and Services Administration, 4350 East West Highway, 10th Floor, Bethesda, MD 20814, Phone (301) 594-4353, Fax (301) 594-4982.

SUPPLEMENTARY INFORMATION: HRSA guidance for the section 340B drug program has described only a discount process for accessing 340B pricing. Although this discount system is functioning successfully for most covered entities, some State AIDS Drug Assistance Programs (ADAPs) have drug purchasing systems that have prevented their participation in the 340B drug program. The use of a rebate mechanism (in addition to the discount mechanism) should allow these groups to access 340B pricing.

Because the rebate mechanism is only a part of a larger endeavor by HRSA to develop the 340B drug program in such a manner as to effectively reach all covered entities, the notice outlining the concept of a narrowly-focused rebate mechanism is withdrawn for further internal deliberation.

Dated: March 14, 1997.

Ciro V. Sumaya,
Administrator.

[FR Doc. 97-7142 Filed 3-20-97; 8:45 am]

BILLING CODE 4160-15-P

National Institutes of Health

Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Advisory Committee on Blood Safety and Availability, Department of Health and Human Services, March 20-21, 1997, which was published in the **Federal Register** on March 3, 1997 (62 FR 9441).

This meeting will be held on April 24-25, 1997, instead of the previously stated March 20-21. The Advisory meeting remains at the same time and place, 8:30 a.m., National Institutes of Health, Warren G. Magnuson Clinical Center, Jack Masur Auditorium, 9000 Rockville Pike, Bethesda, Maryland 20892. As previously stated, this meeting will be entirely open to the public.

On April 24, the Committee will discuss hepatitis C virus (HCV) infection, its occurrence following blood transfusion, other epidemiology of HCV infection and appropriate ways of approaching the public health aspects of this infection. On April 25, the Committee will address multiple aspects of the theoretical possibility that Creutzfeldt-Jakob disease (CJD) can be transmitted by blood transfusion. For each topic, a time will be set aside for the public to comment. Prospective speakers should notify the Executive Secretary for this meeting of their wish to present and should plan for no more than 5 minutes of comments.

CONTACT: Paul R. McCurdy, M.D., Acting Executive Secretary, Advisory Committee on Blood Safety and Availability, Director, Blood Resources Program, DBDR-MS-7950, NHLBI, NIH, Bethesda, Maryland 20892-7950. Phone: 301/435-0065; Fax 301/480-1060; E-Mail: paul_mccurdy@nih.gov.

Dated: March 17, 1997.

LaVerne Y. Stringfield,
Committee Management Officer, NIH.
[FR Doc. 97-7129 Filed 3-20-97; 8:45 am]
BILLING CODE 4140-01-M

National Heart, Lung, and Blood Institutes; Notice of Meeting

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the following National Heart, Lung, and Blood Institutes Special Emphasis Panel.

The meeting will be open to the public to provide concept review of proposed contract or grant solicitations.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should inform the Contract Person listed below in advance of the meeting.

Name of Panel: Stem Cell Transplantation in Sickle Cell Disease.

Dates of Meeting: April 30, 1997.

Time of Meeting: 10:00 a.m.

Place of Meeting: Two Rockledge Center, Rm. 9112, 6701 Rockledge Drive, Bethesda, Maryland 20892.

Agenda: To review current progress and identify future initiatives in the use of stem

cell transplantation for the treatment of sickle cell disease.

Contact Person: Helena Mishoe, Ph.D., NHLBI/DBDR, Two Rockledge Center, 6701 Rockledge Drive, Rm. 10156, MSC 7950, Bethesda, Maryland 20892, (301) 435-0050. (Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: March 17, 1997.

LaVerne Y. Stringfield,
Committee Management Officer, NIH.
[FR Doc. 97-7128 Filed 3-20-97; 8:45 am]

BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Replicating Tumorcidal Viral Therapy for Cancer Applications

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use exclusive license worldwide to practice the invention embodied in U.S. Patent Application Number 07/725,076 (issued on October 25, 1994 as U.S. Patent No. 5,358,866) entitled "Cytosine Deaminase Negative Selection System for Gene Transfer Techniques and Therapies" and its divisional applications 08/271,874, 08/447,580, 08/447,393, 08/445,203, 08/447,487, 08/449,627, 08/448,867, 08/449,636, and all related foreign filings, to ONYX, Inc., having a place of business in Richmond, CA (USA). The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. This notice modifies a previous notice of April 11, 1996 found in Volume 61, Number 71 of the **Federal Register**.

The field of use would be limited to Replicating Tumorcidal Viral Therapy for Cancer applications.

The present inventions relate to a modified bacterial gene for cytosine deaminase. Specifically, the CD gene can be used as a negative selectable